Key result
Tyrosine kinase inhibitors are associated with potential cardiac toxicity, including arrhythmias, ischemic disease, and heart failure, requiring careful monitoring especially in elderly patients.
Why the study?
Despite their efficacy, tyrosine kinase inhibitors present novel side effects, including potential cardiotoxicities such as arrhythmias, cardiac ischemic disease, and heart failure.
What is the cardiotoxicity profile of tyrosine kinase inhibitors in patients with Philadelphia-positive leukemia and other cancers?
What is the cardiotoxicity profile of tyrosine kinase inhibitors in patients with Philadelphia-positive leukemia and other cancers?
Tyrosine kinase inhibitors are associated with potential cardiotoxicity, including arrhythmias, ischemia, and heart failure, necessitating careful monitoring particularly in the elderly.
In the past twenty years, tyrosine kinase inhibitors (TKIs) have substantially changed the therapeutic landscape and the clinical outcome of several cancers, including Philadelphia-chromosome positive chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic syndromes, gastrointestinal stromal tumors, and others. Despite the obvious advantages offered in terms of efficacy and the overall safety profile, this new class of agents presents novel side effects, sometimes different from those induced by conventional chemotherapy. Among others, the potential cardiac toxicity, characterized by possible arrhythmias and the highest rates of cardiac ischemic disease and heart failure, were predominantly investigated. In this article, the authors review the most significant evidence in this regard, highlighting the overall benefit of TKI usage and the need for careful monitoring, especially in elderly patients.
No takes yet. Share an insight, caveat, or question.
Berisha et al. (2023) conducted a review in Philadelphia-chromosome positive leukemia and other cancers. Tyrosine kinase inhibitors (TKIs) was evaluated on Cardiac toxicity (arrhythmias, cardiac ischemic disease, and heart failure). Tyrosine kinase inhibitors are associated with potential cardiac toxicity, including arrhythmias, ischemic disease, and heart failure, requiring careful monitoring especially in elderly patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: